X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Dishman Pharma with Lupin Ltd - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DISHMAN PHARMA vs LUPIN LTD - Comparison Results

DISHMAN PHARMA    Change

Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More

LUPIN LTD 
   Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DISHMAN PHARMA LUPIN LTD DISHMAN PHARMA/
LUPIN LTD
 
P/E (TTM) x 25.1 17.4 143.9% View Chart
P/BV x 3.3 4.1 82.4% View Chart
Dividend Yield % 0.7 0.8 87.6%  

Financials

 DISHMAN PHARMA   LUPIN LTD
EQUITY SHARE DATA
    DISHMAN PHARMA
Mar-16
LUPIN LTD
Mar-16
DISHMAN PHARMA/
LUPIN LTD
5-Yr Chart
Click to enlarge
High Rs3742,127 17.6%   
Low Rs1291,294 10.0%   
Sales per share (Unadj.) Rs197.8304.1 65.0%  
Earnings per share (Unadj.) Rs21.250.4 42.1%  
Cash flow per share (Unadj.) Rs34.760.7 57.2%  
Dividends per share (Unadj.) Rs2.007.50 26.7%  
Dividend yield (eoy) %0.80.4 181.3%  
Book value per share (Unadj.) Rs179.9243.8 73.8%  
Shares outstanding (eoy) m80.69450.58 17.9%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.35.6 22.6%   
Avg P/E ratio x11.933.9 35.0%  
P/CF ratio (eoy) x7.228.2 25.7%  
Price / Book Value ratio x1.47.0 19.9%  
Dividend payout %9.414.9 63.4%   
Avg Mkt Cap Rs m20,306770,740 2.6%   
No. of employees `0000.816.4 5.1%   
Total wages/salary Rs m5,35521,077 25.4%   
Avg. sales/employee Rs Th19,252.78,379.6 229.8%   
Avg. wages/employee Rs Th6,459.51,289.0 501.1%   
Avg. net profit/employee Rs Th2,064.11,388.7 148.6%   
INCOME DATA
Net Sales Rs m15,961137,016 11.6%  
Other income Rs m2651,877 14.1%   
Total revenues Rs m16,226138,893 11.7%   
Gross profit Rs m4,10337,535 10.9%  
Depreciation Rs m1,0914,635 23.5%   
Interest Rs m944446 211.7%   
Profit before tax Rs m2,33434,330 6.8%   
Minority Interest Rs m0-88 0.0%   
Prior Period Items Rs m10-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m62411,536 5.4%   
Profit after tax Rs m1,71122,707 7.5%  
Gross profit margin %25.727.4 93.8%  
Effective tax rate %26.733.6 79.5%   
Net profit margin %10.716.6 64.7%  
BALANCE SHEET DATA
Current assets Rs m11,01897,790 11.3%   
Current liabilities Rs m9,51753,872 17.7%   
Net working cap to sales %9.432.1 29.3%  
Current ratio x1.21.8 63.8%  
Inventory Days Days11085 130.5%  
Debtors Days Days35121 28.7%  
Net fixed assets Rs m16,30486,379 18.9%   
Share capital Rs m161901 17.9%   
"Free" reserves Rs m12,907105,735 12.2%   
Net worth Rs m14,516109,844 13.2%   
Long term debt Rs m4,18953,739 7.8%   
Total assets Rs m29,805224,378 13.3%  
Interest coverage x3.577.9 4.5%   
Debt to equity ratio x0.30.5 59.0%  
Sales to assets ratio x0.50.6 87.7%   
Return on assets %8.910.3 86.3%  
Return on equity %11.820.7 57.0%  
Return on capital %17.521.2 82.7%  
Exports to sales %24.849.1 50.5%   
Imports to sales %3.77.4 50.2%   
Exports (fob) Rs m3,95667,244 5.9%   
Imports (cif) Rs m59610,199 5.8%   
Fx inflow Rs m4,95271,405 6.9%   
Fx outflow Rs m69717,807 3.9%   
Net fx Rs m4,25553,598 7.9%   
CASH FLOW
From Operations Rs m2,786-3,690 -75.5%  
From Investments Rs m-1,529-69,434 2.2%  
From Financial Activity Rs m-94158,126 -1.6%  
Net Cashflow Rs m316-14,998 -2.1%  

Share Holding

Indian Promoters % 61.4 46.6 131.8%  
Foreign collaborators % 0.0 0.2 -  
Indian inst/Mut Fund % 3.7 11.3 32.7%  
FIIs % 12.7 31.9 39.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 22.1 10.1 218.8%  
Shareholders   46,261 98,259 47.1%  
Pledged promoter(s) holding % 35.8 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DISHMAN PHARMA With:   FDC LTD.  UNICHEM LAB  DR. REDDYS LAB  AJANTA PHARMA  ALEMBIC LTD  

Compare DISHMAN PHARMA With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Trades in Green; Lupin up 4%(01:30 pm)

After opening the day flat, share markets in India remained rangebound and are presently trading marginally above the dotted line.

Related Views on News

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Lupin: Decline in US Business Impacts Overall Growth (Quarterly Results Update - Detailed)

May 29, 2017

Currency fluctuation and one time provision impacts operating margins.

Lupin: US Business Drives Growth (Quarterly Results Update - Detailed)

Mar 8, 2017

Lupin has announced its 3QFY17 results. Net sales have grown by 31.5% YoY and net profits have surged by 20.7% YoY. Here is our analysis of the results.

Lupin: Key Products Drive US growth (Quarterly Results Update - Detailed)

Sep 12, 2016

Lupin has announced its 1QFY17results. Net sales have grown by 40% YoY and net profits have surged by 55.1% YoY. Here is our analysis of the results.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

More Views on News

Most Popular

This Small Cap Can Drive Chinese Players Out of India (and Make a Fortune in the Process)(The 5 Minute Wrapup)

Aug 17, 2017

A small-cap Indian company with high-return potential and blue-chip-like stability is set to supplant the Chinese players in this niche segment.

Dear PM Modi, India is Already Land of Self-Employed, and It Ain't Working(Vivek Kaul's Diary)

Aug 21, 2017

Most Indians who cannot find jobs, look at becoming self-employed.

It's the Best Time to Buy IT Stocks(Daily Profit Hunter)

Aug 16, 2017

The IT Sector could be in an uptrend till February 2019. Are you prepared to ride the trend?

5 Steps To Become Financially Independent(Outside View)

Aug 16, 2017

Ensure your financial Independence, and pledge to start the journey towards financial freedom today!

Think Twice Before You Keep Money In A Savings Bank Account(Outside View)

Aug 22, 2017

Post demonetisation, a cut in bank savings deposits rates was in the offing.

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DISHMAN PHARMA SHARE PRICE


May 29, 2017 (Close)

TRACK DISHMAN PHARMA

  • Track your investment in DISHMAN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DISHMAN PHARMA

DISHMAN PHARMA 8-QTR ANALYSIS

COMPARE DISHMAN PHARMA WITH

MARKET STATS